The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?
Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy.
...Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen (PSMA) ligands have demonstrated promising results for the treatment of metastatic castration-resistant prostate cancer. The lack of absorbed-dose-effect relationships currently prevents patient-specific activity personalization. To ease the implementation of dosimet...
Dosimetric Variability Across a Library of Computational Tumor Phantoms
Published in Journal of Nuclear Medicine
In radiopharmaceutical therapy, dosimetry-based treatment planning and response evaluation require accurate estimates of tumor-absorbed dose. Tumor dose estimates are routinely derived using simplistic spherical models, despite the well-established influence of tumor geometry on the dosimetry. Moreover, the degree of disease invasiveness correlates...
Molecular Imaging of Pulmonary Inflammation in Users of Electronic and Combustible Cigarettes: A Pilot Study.
...Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Electronic cigarette (EC) use has increased dramatically, particularly among adolescents and young adults, and, like cigarette use, can cause pulmonary inflammation and increase the risk of lung disease. Methods: This preliminary study used PET with 18F-6-(1/2)(2-fluoro-propyl)-4-methylpyridin-2-amine (18F-NOS) to quantify inducible nitric oxide sy...
Long-Term Prognostic Value of 82Rb PET/CT-Determined Myocardial Perfusion and Flow Reserve in Cancer Patients.
Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Myocardial flow reserve (MFR), derived from quantitative measurements of myocardial blood flow during PET imaging, provides prognostic information on patients with coronary artery disease (CAD), but it is not known if this also applies to cancer patients with a competing risk for mortality. Methods: To determine the prognostic value of MFR in patie...
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzum...
...Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Variations in human epidermal growth factor receptor 2 (HER2) expression between the primary tumor and metastases may contribute to drug resistance in HER2-positive (HER2+) metastatic esophagogastric cancer (mEGC). 89Zr-trastuzumab PET (HER2 PET) holds promise for noninvasive assessment of variations in HER2 expression and target engagement. The ai...
Tau PET Visual Reads: Research and Clinical Applications and Future Directions
Published in Journal of Nuclear Medicine
A Multicenter Study on Observed Discrepancies Between Vendor-Stated and PET-Measured 90Y Activities for Both Glass and R...
Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Dosimetry-guided treatment planning in selective internal radiation therapy relies on accurate and reproducible measurement of administered activity. This 4-center, 5-PET-device study compared the manufacturer-declared 90Y activity in vials with quantitative 90Y PET/CT assessment of the same vials. We compared 90Y PET-measured activity (APET) for 5...
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
...Published in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Targeting of lesions seen on multiparametric MRI (mpMRI) improves prostate cancer (PC) detection at biopsy. However, 20%-65% of highly suspicious lesions on mpMRI (PI-RADS [Prostate Imaging-Reporting and Data System] 4 or 5) are false-positives (FPs), while 5%-10% of clinically significant PC (csPC) are missed. Prostate-specific membrane antigen (P...
Biodistribution, Dosimetry, and Pharmacokinetics of 68Ga-CBP8: A Type I Collagen–Targeted PET Probe
...Published in Journal of Nuclear Medicine
The 68Ga-Collagen Binding Probe #8, 68Ga-CBP8, is a peptide-based, type I collagen–targeted probe developed for imaging of tissue fibrosis. The aim of this study was to determine the biodistribution, dosimetry, and pharmacokinetics of 68Ga-CBP8 in healthy human subjects. Methods: Nine healthy volunteers (5 male and 4 female) underwent whole-body 68...
